TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Tessera Stock

Tessera Stock

www.tesseratherapeutics.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $558.91MM

Tessera Therapeutics is developing a genome engineering technology, Gene Writing™. The goal of Gene Writing™ is to be able to make genomic alterations that can be used to treat or cure disease. Tessera Therapeutics was founded in 2018 by Geoffrey von Maltzahn Ph.D., Jacob Rubens, Ph.D., and Noubar Afeyan, Ph.D. and is headquartered in Cambridge, MA.

Buy or sell Tessera stockLearn more about Tessera IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Tessera, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Tessera’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Tessera.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Tessera investors also invested in these private companies

ARTIS Ventures
Toba Capital
Flagship Pioneering
March Capital
TA Ventures
Longevity Vision Fund

Team

Management Team

Hari Pujar Ph.D
Chief Operating Officer
Madhusudan Peshwa Ph.D
Chief Technology Officer, Cell Therapy
Michael Holmes Ph.D
Chief Scientific Officer
Iain McFadyen Ph.D
Chief Data Officer
Anne-Virginie Eggimann
Chief Regulatory Officer
Michael Severino MD
Chief Executive Officer & Board Member
Howard Liang Ph.D
Chief Financial Officer & President
David Davidson MD
Chief Medical and Development Officer

Frequently Asked Questions About Tessera’s Stock

plusminus
Can you buy Tessera’s stock?
Tessera is not publicly traded on NYSE or NASDAQ in the U.S. To buy Tessera’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Tessera’s stock?
Yes, you can sell stock of a private company like Tessera. Forge can help you sell your Tessera stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Tessera’s stock price?
Tessera is a privately held company and therefore does not have a public stock price. However, you may access Tessera’s private market stock price with Forge Data.
plusminus
What is Tessera’s stock ticker symbol?
Tessera does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Tessera in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Precision Neuroscience

Sector
Healthcare / BioTech & Pharma
 
 

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

BioAge

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$439.94MM

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Life Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$500MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

The Scientist 12/12/2022
Can “Gene Writing” Deliver What Gene Editing Can’t?
For the past few years, a biotech company called Tessera Therapeutics has been working away with a singular, lofty goal in mind: revolutionizing the technology used to edit DNA and RNA for scientific or therapeutic purposes.
Bloomberg's Baystate Business Podcast 04/25/2022
Tessera CEO Interview
Tessera therapeutics has invented a tool for gene writing... Giving promise to entirely new disease therapies and prevention - at the genetic level.
Bloomberg 04/19/2022
Flagship-Backed Tessera Raises $300 Million for Gene-Fixing Tech
Tessera Therapeutics, a company developing a genetic approach to treat and prevent diseases with backing from Flagship Pioneering, raised more than $300 million in its latest round.

Trending Companies

Frequently Asked Questions

Updated on: Apr 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.